|
- About Us - Genentech
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases
- Genentech
AI is evolving how new medicines are being discovered Today, approximately half of Roche and Genentech’s pipeline and marketed medicines derive from successful collaborations with companies and institutions around the world Explore how we are applying computation data science to deliver breakthrough medicines to patients
- Genentech: Our Medicines Products
Genentech has multiple medicines for serious and life-threatening medical conditions Access information and resources on each of our medicines
- Press Releases - Genentech
Discover the latest news about our company, our products, our policies, and our people
- Genentech: Our Medicines
Find important safety information and patient resources for all of our currently marketed medicines
- Careers at Genentech
We believe that a broad spectrum of perspectives drive innovation and contribute towards health impacts for all At Genentech, we value all capabilites and experiences Improving patients’ lives is what we strive to do Each of our 11,800+ employees, from scientists to marketers, advances our mission
- Genentech: Our Pipeline
Rigorous and groundbreaking science has always been at the core of what we do at Genentech Our R D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics
- Genentech: Press Releases | Monday, Mar 3, 2025
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U S Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults
|
|
|